Funder
Amgen
National Cancer Institute
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Oncology
Reference28 articles.
1. Roschewski M, Phelan JD, Wilson WH. Molecular classification and treatment of diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma. Cancer J. 2020;26(3):195–205.
2. Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood. 2010;116(12):2040–5.
3. Friedberg JW. Relapsed/refractory diffuse large B-cell lymphoma. Hematol Am Soc Hematol Educ Program. 2011;2011:498–505.
4. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology - B-Cell Lymphomas, Version 2.2023. 2023. https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf. Accessed 1 May 2023.
5. Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(27):4184–90.